Typically, those patients have a life expectancy of six months or less. In the other four, the cancer stopped progressing. Cell Genesis, Inc., the San Francisco company that makes the vaccine, is modifying the manufacturing technique for expanded trials in five medical centers, he says. The modification is designed to increase the response rate. Nemunaitis also made his research public Monday at the oncology meeting.
Prevention is always better than treatment.
The Memorial Sloan-Kettering Cancer Center has more information about melanoma and lung cancer . Read past HealthScout articles about melanoma and lung cancer . If you're interested in clinical trials for lung cancer, visit Veritas Medicine .